Ishii H
Second Department of Internal Medicine, Okayama University Medical School, Japan.
Acta Med Okayama. 1988 Jun;42(3):175-82. doi: 10.18926/AMO/31031.
Melphalan, ifosfamide, prednisolone, nitrosourea [1-(4-amino-2-methyl-5-pyrimidyl)-3-(2-chloroethyl)-3-nitrosourea hydrochloride, ACNU or 1, 3-bis (2-chloroethyl)-1-nitrosourea, BCNU] and vincristine (MIP-NV) were given in combination to 48 patients with multiple myeloma. The response rate was 57% in previously untreated patients, and 39% in previously treated patients. The median survival time of previously untreated patients in stage IA + IIA was 49 months, and that of patients in stage IIIA + B was 27 months. The median survival time of stage III patients depended significantly on the duration of remission. The duration of remission and survival time of patients with relief of pain and improvement in daily activity were significantly longer than those of patients without such effects. Age, sex, blood hemoglobin concentration and bone lesion were important prognostic factors. As for the side effects, leukopenia (less than 1,000/microliter) and thrombocytopenia (less than 5 X 10(4)/microliter) occurred in 10.4% and 2.1% of the patients, respectively. It was concluded that multiple drug combination therapy with MIP-NV (MIP-NV therapy) was effective for patients with multiple myeloma at all clinical stages, because it resulted in long survival with low toxicity.
美法仑、异环磷酰胺、泼尼松龙、亚硝基脲[1-(4-氨基-2-甲基-5-嘧啶基)-3-(2-氯乙基)-3-亚硝基脲盐酸盐，ACNU或1,3-双(2-氯乙基)-1-亚硝基脲，BCNU]以及长春新碱（MIP-NV）联合应用于48例多发性骨髓瘤患者。既往未治疗患者的缓解率为57%，既往接受过治疗的患者缓解率为39%。IA + IIA期既往未治疗患者的中位生存时间为49个月，IIIA + B期患者为27个月。IIIA期患者的中位生存时间显著取决于缓解期的长短。疼痛缓解且日常活动改善的患者，其缓解期和生存时间显著长于无此类效果的患者。年龄、性别、血红蛋白浓度和骨病变是重要的预后因素。至于副作用，白细胞减少（低于1000/微升）和血小板减少（低于5×10⁴/微升）分别发生在10.4%和2.1%的患者中。得出的结论是，MIP-NV联合多药治疗（MIP-NV治疗）对所有临床分期的多发性骨髓瘤患者均有效，因为它能实现低毒性的长期生存。
